引用本文:王亚乐,谢小倩,赵则月,罗沙沙(综述),李晓天(审校).新型氨基糖苷类药物plazomicin的临床应用研究进展[J].中国临床新医学,2020,13(12):1273-1277.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 62次   下载 68 本文二维码信息
码上扫一扫!
分享到: 微信 更多
新型氨基糖苷类药物plazomicin的临床应用研究进展
王亚乐,谢小倩,赵则月,罗沙沙(综述),李晓天(审校)
471000 洛阳,河南科技大学第一附属医院药学部(王亚乐);450001 河南,郑州大学药学院(谢小倩,赵则月,罗沙沙,李晓天)
摘要:
[摘要]  plazomicin是一种由西索米星为起始原料,经化学合成而得的新型氨基糖苷类药物,对大多数多药耐药菌具有较高的活性。与其他氨基糖苷类药物相似,plazomicin通过与细菌核糖体30S亚基结合抑制细菌蛋白质的合成。对大多数氨基糖苷类修饰酶有效,但不能抑制16S rRNA甲基化酶。该文对plazomicin的化学结构、抗菌机制、耐药机制、体内外抗菌活性、药动学、药效学、临床应用以及药物配伍方面作一综述。
关键词:  Plazomicin  抗菌活性  临床应用  复杂性尿路感染
DOI:10.3969/j.issn.1674-3806.2020.12.23
分类号:R 978.1
基金项目:广西卫健委科研课题(编号:Z20180751,Z20190662)
Research progress in the clinical application of a novel aminoglycoside plazomicin
WANG Ya-le, XIE Xiao-qian, ZHAO Ze-yue, et al.
Department of Pharmacy, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China
Abstract:
[Abstract] Plazomicin is a novel aminoglycoside that is chemically synthesized from sisomicin with enhanced activity against most multidrug-resistant pathogens. Similar to other aminoglycosides, plazomicin inhibits protein synthesis by binding to the bacterial 30S ribosomal subunit. Plazomicin is engineered to overcome the most common aminoglycoside-modifying enzymes, but is not active against 16S rRNA methyltransferase. In this paper, we review the chemical structure, antibacterial mechanism, mechanism of drug resistance, antibacterial activity in vitro and in vivo, pharmacokinetics, pharmacodynamics, clinical application and drug compatibility of plazomicin.
Key words:  Plazomicin  Antibacterial activity  Clinical application  Complicated urinary tract infection(cUTI)